P
Pharma Two B
Striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs, with favorable balance between safety and efficacy
About Pharma Two B
Pharma Two B focuses on developing innovative pharmaceutical products by leveraging previously approved drugs. The company aims to enhance the potential of these drugs by optimizing their mechanism of action, adjusting doses, and improving delivery methods. Additionally, Pharma Two B explores synergistic effects in combination products to create more effective treatments. The primary clients include healthcare providers and pharmaceutical companies looking for advanced therapeutic solutions. Operating in the pharmaceutical and biotechnology market, Pharma Two B employs a business model centered on research and development, followed by licensing and partnerships to bring their products to market. Revenue is generated through licensing agreements, milestone payments, and royalties from product sales.
Source: Dealroom company dataAt a glance
- Founded
- 2007
- Headquarters
- Rehovot, Israel
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Israel Biotech Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pharma Two B on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pharma Two B on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.